GeoVax Labs, Inc. — Q3 2018 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2018. GeoVax is a clinical-stage vaccine biotechnology company; it had no product sales and reported grant and collaboration revenue. Financial statements are unaudited.
Key financial results
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Grant and collaboration revenue | $349,344 | $247,994 | $663,908 | $895,866 |
| Research and development expense | $557,696 | $498,200 | $1,416,892 | $1,568,093 |
| General and administrative expense | $458,974 | $340,143 | $1,175,399 | $985,001 |
| Net loss | $666,893 | $588,757 | $1,925,749 | $1,653,979 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $1,041,485 | $1,240,021 |
- Q3 revenue rose year over year, while nine-month revenue declined, principally reflecting timing and level of grant-related spending and the absence of the $95,000 collaboration revenue recorded in 2017.
- Q3 net loss increased by $78,136; nine-month net loss increased by $271,770. Nine-month total operating expenses were $2,592,291, versus $2,553,094.
- Revenue is primarily government grant reimbursement recognized as eligible costs are incurred; no meaningful product gross margin is reported. The company says it does not expect product revenue for at least several years.
Financial position and liquidity
- At September 30, 2018, cash and cash equivalents were $511,242, total assets $623,467, and current liabilities $1,304,999. Working capital deficit was $708,812, compared with $363,218 at December 31, 2017.
- Liabilities included $1,149,758 of accrued expenses, of which $1,082,135 was deferred management salaries and directors’ fees. Management expected salary deferrals of approximately $36,200 per month to continue until a significant financing event.
- Operating cash use of $1,041,485 was funded primarily by $1,190,000 net proceeds from Series E preferred stock and a $50,000 note. Cash increased by $198,515 over the nine months.
- Total note payable was $50,000, issued to Georgia Research Alliance in February 2018. It bears 5% annual interest; principal repayments begin in 2019.
- Lease obligations and other firm purchase commitments totaled approximately $409,000. The filing says approximately $209,000 of research purchase commitments were expected to be reimbursable under existing grants.
Capital, dilution, and material changes
- GeoVax issued 1,200 Series E preferred shares for $1,190,000 net proceeds during 2018. These shares are convertible at a current $0.02544 per-share conversion price and include price-adjustment provisions.
- The September Series E issuance included warrants for up to 47,169,812 common shares at $0.02544 per share, with anti-dilution and price-adjustment provisions. At September 30, 178,403,476 common shares were outstanding; 196,903,476 were outstanding as of November 8.
- Conversion of 1,000 Series D preferred shares resulted in 66,666,666 common shares during the first nine months. The filing reports approximately 276.0 million potentially dilutive common-share equivalents excluded from diluted loss per share as anti-dilutive.
- Stock-based compensation increased to $275,425 for the first nine months from $43,535 a year earlier, including stock issued for advisory services. This contributed to higher reported G&A; excluding stock compensation, nine-month G&A was $932,195 versus $961,241.
Outlook, risks, and unusual items
- Going concern: Management estimated existing cash and government funding would support planned operations only into mid-January 2019. The filing states substantial doubt about the company’s ability to continue as a going concern beyond that point; management was seeking grants, collaborations, and equity or other financing, but success and terms were uncertain. Failure to raise funds could require delays, reductions, or elimination of programs and cuts to corporate spending.
- GeoVax’s programs include preventive vaccines for HIV, Zika, hemorrhagic fever viruses and malaria, and therapeutic candidates for chronic hepatitis B and cancers. Its most advanced program is an HIV vaccine in human clinical trials. A NIAID-funded Phase 1 trial was ongoing; the company expected another Phase 1 trial to begin in the first half of 2019 and said later support for a larger Phase 2b efficacy trial might follow study results.
- Clinical development, regulatory approval, competition, reliance on grant funding, and access to capital are key risks. The company cautioned that development timing and costs are uncertain and that interim results may not predict full-year results.
- Subsequent to quarter-end, the company issued 5.0 million and 7.5 million common shares for advisory arrangements; the latter issuance eliminated $56,250 of accrued cash retainer fees. It also reported conversion of 90 Series C preferred shares into 6.0 million common shares in October.
- The filing gives two different totals for approved grant funds available: $2,873,542 in the grant-revenue note/table and $2,881,638 in MD&A. The text does not explain the difference.
- Management reported disclosure controls and procedures were effective, no material change in internal control during the quarter, and no legal proceedings or material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether GeoVax obtained sufficient financing after the filing to address the stated mid-January 2019 liquidity horizon and going-concern uncertainty.
- The amount, availability, conditions, and reimbursement timing of grant funds; clarify the conflicting available-funds totals in the filing.
- Actual cash needs, payment timing for deferred compensation and other accrued liabilities, and the status of the company’s research and clinical programs.
- Potential dilution from preferred-stock conversion terms, price adjustments, warrants, options, and subsequent share issuances.
- Progress and funding for the planned HIV clinical trials and whether anticipated milestones or timelines changed.